247 related articles for article (PubMed ID: 20656791)
1. Resistance to transforming growth factor β-mediated tumor suppression in melanoma: are multiple mechanisms in place?
Lasfar A; Cohen-Solal KA
Carcinogenesis; 2010 Oct; 31(10):1710-7. PubMed ID: 20656791
[TBL] [Abstract][Full Text] [Related]
2. Constitutive Smad linker phosphorylation in melanoma: a mechanism of resistance to transforming growth factor-β-mediated growth inhibition.
Cohen-Solal KA; Merrigan KT; Chan JL; Goydos JS; Chen W; Foran DJ; Liu F; Lasfar A; Reiss M
Pigment Cell Melanoma Res; 2011 Jun; 24(3):512-24. PubMed ID: 21477078
[TBL] [Abstract][Full Text] [Related]
3. Transforming growth factor beta(1) selectively inhibits the cyclic AMP-dependent proliferation of primary thyroid epithelial cells by preventing the association of cyclin D3-cdk4 with nuclear p27(kip1).
Depoortere F; Pirson I; Bartek J; Dumont JE; Roger PP
Mol Biol Cell; 2000 Mar; 11(3):1061-76. PubMed ID: 10712520
[TBL] [Abstract][Full Text] [Related]
4. Participation of an abnormality in the transforming growth factor-beta signaling pathway in resistance of malignant glioma cells to growth inhibition induced by that factor.
Zhang L; Sato E; Amagasaki K; Nakao A; Naganuma H
J Neurosurg; 2006 Jul; 105(1):119-28. PubMed ID: 16871886
[TBL] [Abstract][Full Text] [Related]
5. Non-canonical Smads phosphorylation induced by the glutamate release inhibitor, riluzole, through GSK3 activation in melanoma.
Abushahba W; Olabisi OO; Jeong BS; Boregowda RK; Wen Y; Liu F; Goydos JS; Lasfar A; Cohen-Solal KA
PLoS One; 2012; 7(10):e47312. PubMed ID: 23077590
[TBL] [Abstract][Full Text] [Related]
6. Requirement of a dynein light chain in TGFbeta/Smad3 signaling.
Jin Q; Gao G; Mulder KM
J Cell Physiol; 2009 Dec; 221(3):707-15. PubMed ID: 19711352
[TBL] [Abstract][Full Text] [Related]
7. Loss of c-myc repression coincides with ovarian cancer resistance to transforming growth factor beta growth arrest independent of transforming growth factor beta/Smad signaling.
Baldwin RL; Tran H; Karlan BY
Cancer Res; 2003 Mar; 63(6):1413-9. PubMed ID: 12649207
[TBL] [Abstract][Full Text] [Related]
8. Smad2 and Smad3 have differential sensitivity in relaying TGFβ signaling and inversely regulate early lineage specification.
Liu L; Liu X; Ren X; Tian Y; Chen Z; Xu X; Du Y; Jiang C; Fang Y; Liu Z; Fan B; Zhang Q; Jin G; Yang X; Zhang X
Sci Rep; 2016 Feb; 6():21602. PubMed ID: 26905010
[TBL] [Abstract][Full Text] [Related]
9. The leukemia inhibitory factor (LIF) and p21 mediate the TGFβ tumor suppressive effects in human cutaneous melanoma.
Humbert L; Ghozlan M; Canaff L; Tian J; Lebrun JJ
BMC Cancer; 2015 Mar; 15():200. PubMed ID: 25885043
[TBL] [Abstract][Full Text] [Related]
10. Regulatory mechanisms for transforming growth factor beta as an autocrine inhibitor in human hepatocellular carcinoma: implications for roles of smads in its growth.
Matsuzaki K; Date M; Furukawa F; Tahashi Y; Matsushita M; Sugano Y; Yamashiki N; Nakagawa T; Seki T; Nishizawa M; Fujisawa J; Inoue K
Hepatology; 2000 Aug; 32(2):218-27. PubMed ID: 10915727
[TBL] [Abstract][Full Text] [Related]
11. TbetaRI independently activates Smad- and CD2AP-dependent pathways in podocytes.
Xavier S; Niranjan T; Krick S; Zhang T; Ju W; Shaw AS; Schiffer M; Böttinger EP
J Am Soc Nephrol; 2009 Oct; 20(10):2127-37. PubMed ID: 19679673
[TBL] [Abstract][Full Text] [Related]
12. Smad pathway-specific transcriptional regulation of the cell cycle inhibitor p21(WAF1/Cip1).
Pardali K; Kowanetz M; Heldin CH; Moustakas A
J Cell Physiol; 2005 Jul; 204(1):260-72. PubMed ID: 15690394
[TBL] [Abstract][Full Text] [Related]
13. Association of Smads with lymphoid enhancer binding factor 1/T cell-specific factor mediates cooperative signaling by the transforming growth factor-beta and wnt pathways.
Labbé E; Letamendia A; Attisano L
Proc Natl Acad Sci U S A; 2000 Jul; 97(15):8358-63. PubMed ID: 10890911
[TBL] [Abstract][Full Text] [Related]
14. Repression of TGF-beta signaling by the oncogenic protein SKI in human melanomas: consequences for proliferation, survival, and metastasis.
Medrano EE
Oncogene; 2003 May; 22(20):3123-9. PubMed ID: 12793438
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of Id1 by Epstein-Barr virus-encoded LMP1 confers resistance to TGFbeta-mediated growth inhibition.
Lo AK; Dawson CW; Lo KW; Yu Y; Young LS
Mol Cancer; 2010 Jun; 9():155. PubMed ID: 20565867
[TBL] [Abstract][Full Text] [Related]
16. Smad2 and Smad3 are redundantly essential for the TGF-beta-mediated regulation of regulatory T plasticity and Th1 development.
Takimoto T; Wakabayashi Y; Sekiya T; Inoue N; Morita R; Ichiyama K; Takahashi R; Asakawa M; Muto G; Mori T; Hasegawa E; Saika S; Hara T; Nomura M; Yoshimura A
J Immunol; 2010 Jul; 185(2):842-55. PubMed ID: 20548029
[TBL] [Abstract][Full Text] [Related]
17. Insulin-like growth factor-I inhibits transcriptional responses of transforming growth factor-beta by phosphatidylinositol 3-kinase/Akt-dependent suppression of the activation of Smad3 but not Smad2.
Song K; Cornelius SC; Reiss M; Danielpour D
J Biol Chem; 2003 Oct; 278(40):38342-51. PubMed ID: 12876289
[TBL] [Abstract][Full Text] [Related]
18. Modulation of the TGFbeta/Smad signaling pathway in mesangial cells by CTGF/CCN2.
Wahab NA; Weston BS; Mason RM
Exp Cell Res; 2005 Jul; 307(2):305-14. PubMed ID: 15950619
[TBL] [Abstract][Full Text] [Related]
19. Smad expression in human atherosclerotic lesions: evidence for impaired TGF-beta/Smad signaling in smooth muscle cells of fibrofatty lesions.
Kalinina N; Agrotis A; Antropova Y; Ilyinskaya O; Smirnov V; Tararak E; Bobik A
Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1391-6. PubMed ID: 15166010
[TBL] [Abstract][Full Text] [Related]
20. Direct interaction of c-Myc with Smad2 and Smad3 to inhibit TGF-beta-mediated induction of the CDK inhibitor p15(Ink4B).
Feng XH; Liang YY; Liang M; Zhai W; Lin X
Mol Cell; 2002 Jan; 9(1):133-43. PubMed ID: 11804592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
